#1 Clinical Trials Search in Europe

Levomepromazine Hydrochloride

This article explores the use of Levomepromazine Hydrochloride in clinical trials for treating schizophrenia and related disorders. The drug is being studied as part of an early intensified pharmacological treatment (EIPT) approach for patients who have experienced first-line treatment failure. The trial aims to compare the effectiveness of this new approach with treatment as usual (TAU) over a six-week period.

Table of Contents

What is Levomepromazine?

Levomepromazine hydrochloride, also known as methotrimeprazine hydrochloride, is a medication used in the treatment of various mental health conditions[1]. It belongs to a class of drugs called antipsychotics, which work by affecting certain chemicals in the brain to help manage symptoms of mental disorders.

Medical Conditions Treated

Levomepromazine is primarily used to treat conditions such as:

  • Schizophrenia: A mental disorder characterized by distorted thinking, hallucinations, and altered perceptions of reality.
  • Schizoaffective disorder: A condition that combines symptoms of schizophrenia and mood disorders.
  • Schizophreniform disorder: A short-term type of schizophrenia that lasts between one and six months.

These conditions can significantly impact a person’s daily life, affecting their thoughts, emotions, and behaviors[1].

Usage in Clinical Trials

In the clinical trial described, levomepromazine hydrochloride is being used as a comparator drug. This means it’s being compared to other treatments to evaluate their effectiveness[1]. The study aims to investigate the effects of an intensified pharmacological treatment for schizophrenia compared to standard treatment in patients who have experienced a first-time treatment failure.

The trial focuses on patients aged 18 to 70 who have been diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder. It aims to compare changes in symptom severity, functioning, quality of life, and side effects between different treatment approaches[1].

Administration and Dosage

Levomepromazine is typically administered orally. In the clinical trial, the maximum daily dose is set at 600 mg, with a maximum total dose of 25,200 mg over a 6-week treatment period[1]. However, it’s important to note that dosage can vary depending on individual patient needs and should always be determined by a healthcare professional.

Potential Side Effects

As with all medications, levomepromazine can cause side effects. The clinical trial includes assessments of side effects using the General Assessment of Side Effects Scale (GASE)[1]. Common side effects of antipsychotic medications may include:

  • Drowsiness or sedation
  • Dry mouth
  • Blurred vision
  • Constipation
  • Weight gain

It’s important to report any side effects to your healthcare provider promptly.

Important Considerations

When taking levomepromazine, there are several important factors to consider:

  • Pregnancy and breastfeeding: The medication should not be used by pregnant or breastfeeding women[1].
  • Substance use: Patients with current substance use disorders may not be suitable candidates for this medication[1].
  • Medical history: It’s crucial to inform your doctor about any significant diseases or disorders you have, as they may affect your ability to take this medication safely[1].
  • Regular monitoring: Your doctor may require regular check-ups and laboratory tests to monitor your response to the medication and check for any potential side effects[1].

Remember, levomepromazine should only be taken under the supervision of a healthcare professional. Never adjust your dosage or stop taking the medication without consulting your doctor first.

Aspect Details
Drug Name Levomepromazine Hydrochloride (also known as Methotrimeprazine Hydrochloride)
Trial Purpose To compare early intensified pharmacological treatment (EIPT) with treatment as usual (TAU) for schizophrenia and related disorders
Target Conditions Schizophrenia, schizoaffective disorder, schizophreniform disorder
Trial Duration 6 weeks
Maximum Daily Dose 600 mg
Administration Route Oral
Primary Outcome Measure Change in PANSS total score
Key Eligibility Criteria Age 18-70, diagnosed with target conditions, experienced first treatment failure, meets symptom severity threshold

FAQ

  • What is Levomepromazine Hydrochloride? Levomepromazine Hydrochloride is an antipsychotic medication being studied as a potential treatment for schizophrenia and related disorders. It is part of a group of drugs called phenothiazines and is also known as Methotrimeprazine Hydrochloride.
  • What is the main goal of the clinical trial involving Levomepromazine Hydrochloride? The main goal is to compare the effectiveness of an early intensified pharmacological treatment (EIPT), which includes Levomepromazine Hydrochloride, with treatment as usual (TAU) in patients who have experienced first-line treatment failure for schizophrenia, schizoaffective disorder, or schizophreniform disorder.
  • How long does the clinical trial last? The clinical trial lasts for six weeks, during which the researchers compare the changes in symptom severity between the EIPT group and the TAU group.
  • What is the maximum daily dose of Levomepromazine Hydrochloride used in the trial? The maximum daily dose of Levomepromazine Hydrochloride used in the trial is 600 mg.
  • Who can participate in this clinical trial? Participants must be between 18 and 70 years old, diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder, and have experienced their first treatment failure on a first-line medication. They must also meet specific symptom severity criteria and be willing to change their current medication.

Ongoing Clinical Trials on Levomepromazine Hydrochloride

  • Study on the Effect of Clozapine and Drug Combination for Patients with Schizophrenia Experiencing First-Line Treatment Failure

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany Italy Spain

  • Study on Reducing Antipsychotic Dose vs. Maintenance Treatment for Patients with Schizophrenia Using Haloperidol Decanoate, Risperidone, and Amisulpride

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    France

Glossary

  • Schizophrenia: A serious mental disorder characterized by distortions in thinking, perception, emotions, language, sense of self, and behavior.
  • Schizoaffective disorder: A mental health condition that includes symptoms of both schizophrenia and mood disorders, such as depression or bipolar disorder.
  • Schizophreniform disorder: A short-term type of schizophrenia that lasts between one and six months.
  • PANSS: Positive and Negative Syndrome Scale, a tool used to measure symptom severity in schizophrenia.
  • CGI: Clinical Global Impression Scale, used to assess the severity and improvement of mental health conditions.
  • Early Intensified Pharmacological Treatment (EIPT): An approach that involves using stronger or different medications earlier in the treatment process to potentially improve outcomes.
  • Treatment as Usual (TAU): The standard treatment approach typically used for a particular condition.
  • Antipsychotic: A type of medication used to manage psychosis, including delusions, hallucinations, and disordered thinking.
  • Phenothiazines: A class of antipsychotic medications, to which Levomepromazine Hydrochloride belongs.
  • First-line treatment: The initial treatment typically recommended and used for a particular condition.
  • Treatment failure: When a medication or treatment approach does not effectively manage symptoms or improve the patient's condition.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effect-of-clozapine-and-drug-combination-for-patients-with-schizophrenia-experiencing-first-line-treatment-failure/